The main aim of the study is to estimate the potential efficacy of i.v. canrenone as add-on therapy on maximal medical treatment versus maximal medical treatment alone in treating moderate-to-severe ARDS due to SARS-CoV-2.
Drug: Potassium Canrenoate
potassium canrenoate for 7 days in addition to maximal medical treatment
Other Name: Canrenone
Inclusion Criteria: - Age 18 - 80 y.o. Since over eighties are very fragile patients, a lot of confounding unpredictable events may interfere with the trial analyses; thus, these patients will be excluded from this exploratory proof-of-concept trial; - COVID-19 diagnosis through swab within 14 days from the beginning of symptoms - Hospitalization for moderate to severe ARDS (as determined by PaO2/FiO2 ≤300 mmHg at admission) - Serum concentration of potassium ≤4.5 mEq/L - Consent to participate
Exclusion Criteria: - Invasive mechanical ventilation - I.v. hydratation with Darrow's solution or half-strength Darrow's solution underway - Acute cardiovascular event (acute myocardial infarction, acute ischaemic stroke) - Current malignant disease - Creatinine >1.8 mg/dL (for women) and >2.0 mg/dL (for men) or glomerular filtration rate
Marco Vicenzi, MD
+390255033537
marco.vicenzi@policlinico.mi.it
Marco Vicenzi, MD
Principal Investigator
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico